Family Practice Assocs Of Clarksville

CLIA Laboratory Citation Details

5
Total Citations
16
Total Deficiencyies
12
Unique D-Tags
CMS Certification Number 04D0906636
Address 23 Professional Park Drive, Clarksville, AR, 72830
City Clarksville
State AR
Zip Code72830
Phone479 754-4721
Lab DirectorSCOTT KUYKENDALL

Citation History (5 surveys)

Survey - September 10, 2025

Survey Type: Standard

Survey Event ID: LYPM11

Deficiency Tags: D5783

Summary:

Summary Statement of Deficiencies D5783

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - October 29, 2024

Survey Type: Special

Survey Event ID: 3YKQ11

Deficiency Tags: D2016 D2107 D6000 D2096 D2108 D6016

Summary:

Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Review of the 2024 CMS Casper Reports 096D, 0153D, and the American Proficiency Institute (API) proficiency testing results, showed the laboratory failed to have initial successful participation in proficiency testing for the analytes Total Cholesterol (CHOL), Free Thyroxine (TY), Thyroid-stimulating Hormone (TSH) and the subspecialty of Endocrinology. Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance as cited at D2096, D2107, and D2108. D2096 ROUTINE CHEMISTRY Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- CFR(s): 493.841(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the 2024 CMS Casper Reports 096D, 0153D and API proficiency testing results, it was determined the laboratory failed to have satisfactory participation in proficiency testing for the analyte CHOL. Survey Findings follow: A. A review of the proficiency testing results revealed the laboratory received a score of 0% for the analyte CHOL in the first proficiency testing event of 2024. B. A review of the proficiency testing results revealed the laboratory received a score of 60% for the analyte CHOL in the third proficiency testing event of 2024. D2107 ENDOCRINOLOGY CFR(s): 493.843(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the 2024 CMS Casper Reports 096D, 0153D and API proficiency testing results, it was determined the laboratory failed to have satisfactory participation in proficiency testing for the analytes TY and TSH. Survey Findings follow: A. A review of the proficiency testing results revealed the laboratory received a score of 0% for the analyte TSH and a 20% for the analyte TY in the second proficiency testing event of 2024. B. A review of the proficiency testing results revealed the laboratory received a score of 0% for the analytes TSH and TY in the third proficiency testing event of 2024. D2108 ENDOCRINOLOGY CFR(s): 493.843(g) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the 2024 CMS Casper Reports 096D, 0153D and API proficiency testing results, it was determined the laboratory failed to have satisfactory participation in proficiency testing for the subspecialty of Endocrinology. Survey Findings follow: A. A review of the proficiency testing results revealed the laboratory received an overall score of 40% for the for the subspecialty of Endocrinology in the second proficiency testing event of 2024. B. A review of the proficiency testing results revealed the laboratory received a score of 26% for the subspecialty of Endocrinology in the third proficiency testing event of 2024. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR -- 2 of 3 -- CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Review of 2024 proficiency testing results, showed the laboratory director failed to ensure that the proficiency testing samples are tested as required under Subpart H of this part. Refer to D6016. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Review of the 2024 proficiency testing events, showed the laboratory director failed to ensure the laboratory successfully participated in proficiency testing for the Routine Chemistry Test CHOL, the Endocrinology tests of TY and TSH, and the overall subspecialty of Endocrinology. Refer to D2096, D2107, and D2108. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - December 7, 2023

Survey Type: Standard

Survey Event ID: FCYD11

Deficiency Tags: D5417

Summary:

Summary Statement of Deficiencies D5417 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(d) Reagents, solutions, culture media, control materials, calibration materials, and other supplies must not be used when they have exceeded their expiration date, have deteriorated, or are of substandard quality. This STANDARD is not met as evidenced by: Through observation and interview with laboratory staff it was determined that the laboratory had supplies available for use after their expiration date. Findings follow: A) During a tour of the laboratory on 12/07/23 at 2:46 p.m. one (of one) ISE Cleaning Solution / Elecsys Sysclean (Lot: 62235301, ref: 11298500160, expiration date 11/30 /23) was observed in the laboratory. C) In an interview on 12/07/23 at 2:46 p.m laboratory staff member (listed as #3 on the CMS 209 form) confirmed that the items, identified above, had exceeded their expiration date and were available for use. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - May 23, 2019

Survey Type: Standard

Survey Event ID: 52SQ11

Deficiency Tags: D2015 D5445 D2009 D5417

Summary:

Summary Statement of Deficiencies D2009 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(1) The individual testing or examining the samples and the laboratory director must attest to the routine integration of the samples into the patient workload using the laboratory's routine methods. This STANDARD is not met as evidenced by: Through a review of the proficiency test attestation records for 2018 and 2019, and interview with laboratory staff, it was determined the testing personnel failed to attest to the routine integration of proficiency test samples in the patient workload for four of four surveys reviewed. Survey findings follow: A) The attestation forms for the following proficiency test events were not signed by the testing personnel: AAFP- 2018 Event A, AAFP-2018 Event B, AAFP-2018 Event C and AAFP-2019 Event A. B) In an interview, at approximately 11:10 on 5/22/19, the laboratory director (as listed on the form CMS-209) stated that testing personnel had not signed the attestation forms identified above and the laboratory director had printed the names of the testing personnel on the attestation forms. D2015 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(5)(6) (5) The laboratory must document the handling, preparation, processing, examination, and each step in the testing and reporting of results for all proficiency testing samples. The laboratory must maintain a copy of all records, including a copy of the proficiency testing program report forms used by the laboratory to record proficiency testing results including the attestation statement provided by the PT program, signed by the analyst and the laboratory director, documenting that proficiency testing samples were tested in the same manner as patient specimens, for a minimum of two years from the date of the proficiency testing event. (6) PT is required for only the test Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- system, assay, or examination used as the primary method for patient testing during the PT event. This STANDARD is not met as evidenced by: Through a review of proficiency test documentation for 2018 and 2019, lack of documentation, and interview with laboratory staff, it was determined the laboratory failed to maintain copies of proficiency test instrument print-outs for four of four proficiency test events surveyed. Survey findings follow: A) Review of proficiency testing documentation for AAFP-2018 Event A, AAFP-2018 Event B, AAFP-2018 Event C, and AAFP-2019 Event A revealed that original instrument result print-outs were not included in the documentastion. B) Upon request, the laboratory was unable to produce the instrument print-outs for the events identified above. C) In an interview on 5/22/19 at approximately 11:10 AM, the laboratory director identified on the CMS 209 form confirmed that the instrument print-outs for the events identified above were not available. D5417 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(d) Reagents, solutions, culture media, control materials, calibration materials, and other supplies must not be used when they have exceeded their expiration date, have deteriorated, or are of substandard quality. This STANDARD is not met as evidenced by: Through observations made during a tour of the laboratory and interview it was determined the laboratory had reagent available for use when it had exceeded the expiration date. Survey findings follow: A) During a tour of the laboratory at approximately 10:45 AM on 5/23/19, one of two bottles of HCG Tri-Level Control (Lot # 170371 expiration date 2019-01-31) was observed available for use on the counter where qualitative testing is performed. B) In an interview on 5/23/19 at approximately 10:45 AM, the laboratoery director, identified as number one on the CMS 209 form, confirmed that the HCG control identified above had exceeded its date of expiration and was available for use. D5445 CONTROL PROCEDURES CFR(s): 493.1256(d)(1)(2)(g) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- (d)(1) Perform control procedures as defined in this section unless otherwise specified in the additional specialty and subspecialty requirements at 493.1261 through 493.1278. (d)(2) For each test system, perform control procedures using the number and frequency specified by the manufacturer or established by the laboratory when they meet or exceed the requirements in paragraph (d)(3) of this section. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Through review of the laboratory's "Quality Control Policy", quality control summary reports, lack of documentation, "Result Listing" report for 10/17/18, and interview it was determined that the laboratory failed to perform quality controls for quantitative -- 2 of 3 -- chemistry testing on one of twenty-three days of testing in October 2018. Survey findings follow: A) Review of the laboratory's "Quality Control Policy" revealed that "controls will be run each day of testing before patient results are reported". B) Review of October 2018 quality control summary reports for the Integra 400 chemistry analyzer revealed that no quality control results were listed for October 17, 2018. C) Upon request, the laboratory was unable to produce quality control results for the Integra chemistry analyzer for October 17, 2018. D) Review of the "result listing" report revealed that chemistry testing performed on the Integra 400 chemistry analyzer was reported on fourteen patients, identified as numbers one through fourteen on a separate patient identification list. E) In an interview on May 22, 2019 at approximately 02:55 PM, the laboratory director, identified on the CMS 209 form, confirmed that Integra 400 chemistry quality control was not performed on October 17, 2018 and patient results were reported. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - May 29, 2018

Survey Type: Special

Survey Event ID: 2ZCG11

Deficiency Tags: D2016 D6000 D2096 D6019

Summary:

Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: . Based on review of 2017 and 2018 CMS Casper Reports 0155D, 0153D, and the American Academy of Family Physicians (AAFP) proficiency testing results, it was determined the laboratory failed to have successful participation in proficiency testing for the analyte Chloride (CL) in two consecutive testing events. As evidenced by: Failure to achieve satisfactory performance for the same analyte in two consecutive testing events is unsuccessful performance as cited at D2096. D2096 ROUTINE CHEMISTRY CFR(s): 493.841(f) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: . Based on review of 2017 and 2018 CMS Casper Reports 0155D and 0153D and the American Academy of Family Physicans proficiency testing results, it was determined the laboratory failed to have satisfactory participation in proficiency testing for the analyte Chloride (CL) . As evidenced by: A. The laboratory received a sore of 40% in third proficiency testing event of 2017 for the analyte CL. B. The laboratory received a score of 40% in the first proficiency testing event of 2018 for the analyte CL. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: . Based on a review of the 2017 and 2018 proficiency testing results, it was determined the Laboratory Director failed to ensure that

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access